Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Hangzhou Jiuyuan Genetic Biopharmaceutical Co had a gross margin of 79.22% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Gross Margin % Related Terms
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Gross Margin % Chart
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Annual Data
Trend
Dec21
Dec22
Dec23
Dec24
Dec25
Gross Margin %
72.70
75.91
76.95
79.00
80.69
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Semi-Annual Data
HKSE:02566 vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Gross Margin % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) has a Gross Margin % of 79.22% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Hangzhou Jiuyuan Genetic Biopharmaceutical Co and its competitors. This is near median its historical median of 76.95. Over the past decade, Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Gross Margin % has ranged from 72.70 to 80.69. According to the industry distribution chart, Hangzhou Jiuyuan Genetic Biopharmaceutical Co ranks #200 out of 735 companies in the Biotechnology industry, placing it in the top 27.2%.
Is Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Gross Margin % too high?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co's current Gross Margin % of 79.22% is near median its 10-year median of 76.95. Over the past 10 years, this metric has ranged from a low of 72.70 to a high of 80.69. The Biotechnology industry median Gross Margin % is 60.91. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's value of 79.22% is 30.1% above this industry median. Based on the distribution chart, Hangzhou Jiuyuan Genetic Biopharmaceutical Co ranks #200 out of 735 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Hangzhou Jiuyuan Genetic Biopharmaceutical Co has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hangzhou Jiuyuan Genetic Biopharmaceutical Co ranks #200 out of 735 companies for Gross Margin %. This puts Hangzhou Jiuyuan Genetic Biopharmaceutical Co in the upper half of its industry. The industry median Gross Margin % is 60.91. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's value of 79.22% is 30.1% above this benchmark. Historically, Hangzhou Jiuyuan Genetic Biopharmaceutical Co's own Gross Margin % has ranged from 72.70 to 80.69 over the past decade. While the company's 10-year median is 76.95 vs. the industry median of 60.91, Hangzhou Jiuyuan Genetic Biopharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's current Gross Margin % of 79.22% is 30.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Hangzhou Jiuyuan Genetic Biopharmaceutical Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's current Gross Margin % is 79.22%, which is near median its own 10-year median of 76.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Jiuyuan Genetic Biopharmaceutical Co stock overvalued right now?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) has a current Gross Margin % of 79.22%. The current Gross Margin % is 79.22%, which is near median its 10-year median of 76.95 and 30.1% above the Biotechnology industry median of 60.91. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566), the current Gross Margin % is 79.22% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd is a biopharmaceutical company in China. It is engaged in the research & development, manufacturing, and commercialization of biopharmaceutical products and medical devices. The company focuses on four large and fast-growing therapeutic areas: orthopedics, metabolic diseases, oncology, and hematology. Centered around these therapeutic areas, it has built a diversified product portfolio comprising several marketed products, such as Jilifen, Jijufen, Jiouting, Yinuojia, Guyoudao, etc., and has several product candidates under development, such as JY54, JY23, JY47, JY56, JY29-2, etc., targeting various indications. Geographically, the company generates maximum revenue from the Chinese Mainland, and the rest from other countries.
20GF Score
Get the complete analysis for HKSE:02566
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02566 has been successfully added to your 
